User:Eliška Koutná/Sandbox 1
From Proteopedia
< User:Eliška Koutná(Difference between revisions)
| Line 22: | Line 22: | ||
== Prion diseases == | == Prion diseases == | ||
| - | Up to this date, many different types of TSEs are known ([[#General intro|see General intro]]), affecting many animal species as well as humans and showing various symptoms. As was mentioned in previous chapters, all prion diseases promote their negative effects through accumulation of PrPSc in the CNS. However, since most of the TSEs are transmitted by peripheral routes, either orally or transcutaneously, events critical for their pathogenesis take place at peripheral parts of the organism, especially in peripheral lymph organs <ref>DOI 10.1006/clim.2000.4875</ref>. | + | Up to this date, many different types of TSEs are known ([[#General intro|see General intro]]), affecting many animal species as well as humans and showing various symptoms. As was mentioned in previous chapters, all prion diseases promote their negative effects through accumulation of PrPSc in the CNS. However, since most of the TSEs are transmitted by peripheral routes, either orally or transcutaneously, events critical for their pathogenesis take place at peripheral parts of the organism, especially in peripheral lymph organs <ref>DOI 10.1006/clim.2000.4875</ref>. In the following text, probably the two most important prion diseases and facts known about their mechanism of infection are described. |
=== Bovine spongiform encephalopathy === | === Bovine spongiform encephalopathy === | ||
Commonly known as the mad cow disease, bovine spongiform encephalopathy (BSE) is a type of prion disease that affects cattle. Among major symptoms observed in affected animals are abnormal behavior, anxiety, ataxia, hypersensitivity to touch and noise and poor body condition – from movement and posture problems all the way down up to paralysis. Onset symptoms usually emerge after 4-4.5 years from the infection <ref>DOI 10.1016/B978-0-444-63945-5.00007-6</ref>. From that point, the disease is very progressive in degeneration of animal’s nervous system and leads to its death, generally within the time horizon of weeks to months <ref>PMID 15581140</ref>. | Commonly known as the mad cow disease, bovine spongiform encephalopathy (BSE) is a type of prion disease that affects cattle. Among major symptoms observed in affected animals are abnormal behavior, anxiety, ataxia, hypersensitivity to touch and noise and poor body condition – from movement and posture problems all the way down up to paralysis. Onset symptoms usually emerge after 4-4.5 years from the infection <ref>DOI 10.1016/B978-0-444-63945-5.00007-6</ref>. From that point, the disease is very progressive in degeneration of animal’s nervous system and leads to its death, generally within the time horizon of weeks to months <ref>PMID 15581140</ref>. | ||
| Line 35: | Line 35: | ||
The vCJD form was described for the first time during the BSE epidemic in the United Kingdom in 1996 and was termed as the “new variant CJD” <ref>PMID 8598754</ref>. It is primarily caused by ingestion of food with infectious contamination originating from BSE affected cattle <ref>DOI 10.1002/ana.20708</ref>. Nonetheless, infection can also arise from transfusion by an infected blood <ref>DOI 10.1111/vox.12371</ref> or a blood product, i.e. factor VIII important in the pathway of the blood coagulation <ref>DOI 10.1111/j.1365-2516.2009.02181.x</ref>. The BSE epidemic is the main reason for which the vCJD still occurs with highest incidence in the UK and France. Since the 1996 till 25.04.2017, total count of 231 definite or probable cases of vCJD was reported <ref name="knight">. Symptoms of vCJD are again mostly identical or very similar to those of other CJD forms, including painful sensory symptoms and involuntary movements <ref>DOI 10.1136/jnnp.2010.232264</ref>. In compare with sCJD, mean survival of patients from the onset symptoms is significantly longer, approximately 14 months from the onset symptoms <ref>DOI 10.1002/ana.21987</ref>. | The vCJD form was described for the first time during the BSE epidemic in the United Kingdom in 1996 and was termed as the “new variant CJD” <ref>PMID 8598754</ref>. It is primarily caused by ingestion of food with infectious contamination originating from BSE affected cattle <ref>DOI 10.1002/ana.20708</ref>. Nonetheless, infection can also arise from transfusion by an infected blood <ref>DOI 10.1111/vox.12371</ref> or a blood product, i.e. factor VIII important in the pathway of the blood coagulation <ref>DOI 10.1111/j.1365-2516.2009.02181.x</ref>. The BSE epidemic is the main reason for which the vCJD still occurs with highest incidence in the UK and France. Since the 1996 till 25.04.2017, total count of 231 definite or probable cases of vCJD was reported <ref name="knight">. Symptoms of vCJD are again mostly identical or very similar to those of other CJD forms, including painful sensory symptoms and involuntary movements <ref>DOI 10.1136/jnnp.2010.232264</ref>. In compare with sCJD, mean survival of patients from the onset symptoms is significantly longer, approximately 14 months from the onset symptoms <ref>DOI 10.1002/ana.21987</ref>. | ||
| - | The susceptibility to infection and disease, incubation period and duration of survival in all CJD forms are dependent on several different factors including age of onset and genetic predispositions. So called PRNP-129 polymorphism is related to all CJD forms, but especially to iCJD. Its principle lies in genotype combinations of Met129 and Val129 alleles (MM, MV or VV) and in iCJD, it has substantial impact on susceptibility and incubation period of the disease caused by infection from previously mentioned treatment with hGH <ref name="brandel">PMID 12867116</ref>. It appears that VV and mainly MM homozygotes are significantly more susceptible to infection by CJD and have shorter incubation period than MV heterozygotes <ref name="brandel"> <ref | + | The susceptibility to infection and disease, incubation period and duration of survival in all CJD forms are dependent on several different factors including age of onset and genetic predispositions. So called PRNP-129 polymorphism is related to all CJD forms, but especially to iCJD. Its principle lies in genotype combinations of Met129 and Val129 alleles (MM, MV or VV) and in iCJD, it has substantial impact on susceptibility and incubation period of the disease caused by infection from previously mentioned treatment with hGH <ref name="brandel">PMID 12867116</ref>. It appears that VV and mainly MM homozygotes are significantly more susceptible to infection by CJD and have shorter incubation period than MV heterozygotes <ref name="brandel"> <ref>PMID 10443888</ref>. Almost all definite and probable vCJD and sCJD reported cases are of MM genotype, further supporting this hypothesis <ref name="kaski">DOI 10.1016/S0140-6736(09)61568-3</ref>. |
== Diagnosis and treatment == | == Diagnosis and treatment == | ||
Current revision
Prions
| |||||||||||
References
- ↑ Imran M, Mahmood S. An overview of animal prion diseases. Virol J. 2011 Nov 1;8:493. doi: 10.1186/1743-422X-8-493. PMID:22044871 doi:http://dx.doi.org/10.1186/1743-422X-8-493
- ↑ Prusiner SB. Prion diseases and the BSE crisis. Science. 1997 Oct 10;278(5336):245-51. doi: 10.1126/science.278.5336.245. PMID:9323196 doi:http://dx.doi.org/10.1126/science.278.5336.245
- ↑ 3.0 3.1 3.2 3.3 Sigurdson CJ, Bartz JC, Glatzel M. Cellular and Molecular Mechanisms of Prion Disease. Annu Rev Pathol. 2019 Jan 24;14:497-516. doi:, 10.1146/annurev-pathmechdis-012418-013109. Epub 2018 Oct 24. PMID:30355150 doi:http://dx.doi.org/10.1146/annurev-pathmechdis-012418-013109
- ↑ Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K. NMR structure of the mouse prion protein domain PrP(121-321). Nature. 1996 Jul 11;382(6587):180-2. PMID:8700211 doi:10.1038/382180a0
- ↑ doi: https://dx.doi.org/10.1073/pnas.97.1.145
- ↑ Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, Raymond L, Favara C, Baron G, Priola S, Caughey B, Masliah E, Oldstone M. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science. 2005 Jun 3;308(5727):1435-9. doi: 10.1126/science.1110837. PMID:15933194 doi:http://dx.doi.org/10.1126/science.1110837
- ↑ 7.0 7.1 7.2 7.3 Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE, et al.. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10962-6. PMID:7902575
- ↑ Wille H, Requena JR. The Structure of PrP(Sc) Prions. Pathogens. 2018 Feb 7;7(1). pii: pathogens7010020. doi: 10.3390/pathogens7010020. PMID:29414853 doi:http://dx.doi.org/10.3390/pathogens7010020
- ↑ 9.0 9.1 9.2 9.3 Cohen FE, Prusiner SB. Pathologic conformations of prion proteins. Annu Rev Biochem. 1998;67:793-819. doi: 10.1146/annurev.biochem.67.1.793. PMID:9759504 doi:http://dx.doi.org/10.1146/annurev.biochem.67.1.793
- ↑ 10.2210/pdb4E1I/pdb
- ↑ 11.0 11.1 11.2 doi: https://dx.doi.org/10.1126/science.7909169
- ↑ Deleault NR, Lucassen RW, Supattapone S. RNA molecules stimulate prion protein conversion. Nature. 2003 Oct 16;425(6959):717-20. doi: 10.1038/nature01979. PMID:14562104 doi:http://dx.doi.org/10.1038/nature01979
- ↑ 13.0 13.1 Khanam H, Ali A, Asif M, Shamsuzzaman. Neurodegenerative diseases linked to misfolded proteins and their therapeutic approaches: A review. Eur J Med Chem. 2016 Nov 29;124:1121-1141. doi: 10.1016/j.ejmech.2016.08.006., Epub 2016 Aug 6. PMID:27597727 doi:http://dx.doi.org/10.1016/j.ejmech.2016.08.006
- ↑ Aucouturier P, Carp RI, Carnaud C, Wisniewski T. Prion diseases and the immune system. Clin Immunol. 2000 Aug;96(2):79-85. doi: 10.1006/clim.2000.4875. PMID:10900153 doi:http://dx.doi.org/10.1006/clim.2000.4875
- ↑ Casalone C, Hope J. Atypical and classic bovine spongiform encephalopathy. Handb Clin Neurol. 2018;153:121-134. doi: 10.1016/B978-0-444-63945-5.00007-6. PMID:29887132 doi:http://dx.doi.org/10.1016/B978-0-444-63945-5.00007-6
- ↑ Konold T, Bone G, Ryder S, Hawkins SA, Courtin F, Berthelin-Baker C. Clinical findings in 78 suspected cases of bovine spongiform encephalopathy in Great Britain. Vet Rec. 2004 Nov 20;155(21):659-66. PMID:15581140
- ↑ doi: https://dx.doi.org/10.1111/j.1749-6632.1994.tb38911.x
- ↑ Espinosa JC, Morales M, Castilla J, Rogers M, Torres JM. Progression of prion infectivity in asymptomatic cattle after oral bovine spongiform encephalopathy challenge. J Gen Virol. 2007 Apr;88(Pt 4):1379-83. doi: 10.1099/vir.0.82647-0. PMID:17374785 doi:http://dx.doi.org/10.1099/vir.0.82647-0
- ↑ 19.0 19.1 19.2 Knight R. Infectious and Sporadic Prion Diseases. Prog Mol Biol Transl Sci. 2017;150:293-318. doi: 10.1016/bs.pmbts.2017.06.010., Epub 2017 Aug 14. PMID:28838665 doi:http://dx.doi.org/10.1016/bs.pmbts.2017.06.010
- ↑ Mackenzie G, Will R. Creutzfeldt-Jakob disease: recent developments. F1000Res. 2017 Nov 27;6:2053. doi: 10.12688/f1000research.12681.1. eCollection, 2017. PMID:29225787 doi:http://dx.doi.org/10.12688/f1000research.12681.1
- ↑ Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, Klug GM, Sutcliffe T, Giulivi A, Alperovitch A, Delasnerie-Laupretre N, Brandel JP, Poser S, Kretzschmar H, Rietveld I, Mitrova E, Cuesta Jde P, Martinez-Martin P, Glatzel M, Aguzzi A, Knight R, Ward H, Pocchiari M, van Duijn CM, Will RG, Zerr I. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005 May 10;64(9):1586-91. doi: 10.1212/01.WNL.0000160117.56690.B2. PMID:15883321 doi:http://dx.doi.org/10.1212/01.WNL.0000160117.56690.B2
- ↑ Maddox RA, Belay ED, Curns AT, Zou WQ, Nowicki S, Lembach RG, Geschwind MD, Haman A, Shinozaki N, Nakamura Y, Borer MJ, Schonberger LB. Creutzfeldt-Jakob disease in recipients of corneal transplants. Cornea. 2008 Aug;27(7):851-4. doi: 10.1097/ICO.0b013e31816a628d. PMID:18650677 doi:http://dx.doi.org/10.1097/ICO.0b013e31816a628d
- ↑ Peden AH, Ritchie DL, Uddin HP, Dean AF, Schiller KA, Head MW, Ironside JW. Abnormal prion protein in the pituitary in sporadic and variant Creutzfeldt-Jakob disease. J Gen Virol. 2007 Mar;88(Pt 3):1068-72. doi: 10.1099/vir.0.81913-0. PMID:17325383 doi:http://dx.doi.org/10.1099/vir.0.81913-0
- ↑ Cochius JI, Hyman N, Esiri MM. Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin: a second case. J Neurol Neurosurg Psychiatry. 1992 Nov;55(11):1094-5. PMID:1469410
- ↑ Rudge P, Jaunmuktane Z, Adlard P, Bjurstrom N, Caine D, Lowe J, Norsworthy P, Hummerich H, Druyeh R, Wadsworth JD, Brandner S, Hyare H, Mead S, Collinge J. Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain. 2015 Nov;138(Pt 11):3386-99. doi: 10.1093/brain/awv235. Epub 2015 Aug 11. PMID:26268531 doi:http://dx.doi.org/10.1093/brain/awv235
- ↑ Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996 Apr 6;347(9006):921-5. PMID:8598754
- ↑ Ward HJ, Everington D, Cousens SN, Smith-Bathgate B, Leitch M, Cooper S, Heath C, Knight RS, Smith PG, Will RG. Risk factors for variant Creutzfeldt-Jakob disease: a case-control study. Ann Neurol. 2006 Jan;59(1):111-20. doi: 10.1002/ana.20708. PMID:16287153 doi:http://dx.doi.org/10.1002/ana.20708
- ↑ Urwin PJ, Mackenzie JM, Llewelyn CA, Will RG, Hewitt PE. Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review Study. Vox Sang. 2016 May;110(4):310-6. doi: 10.1111/vox.12371. Epub 2015 Dec 28. PMID:26709606 doi:http://dx.doi.org/10.1111/vox.12371
- ↑ Peden A, McCardle L, Head MW, Love S, Ward HJ, Cousens SN, Keeling DM, Millar CM, Hill FG, Ironside JW. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia. 2010 Mar;16(2):296-304. doi: 10.1111/j.1365-2516.2009.02181.x. Epub , 2010 Jan 12. PMID:20070383 doi:http://dx.doi.org/10.1111/j.1365-2516.2009.02181.x
- ↑ Heath CA, Cooper SA, Murray K, Lowman A, Henry C, MacLeod MA, Stewart GE, Zeidler M, MacKenzie JM, Ironside JW, Summers DM, Knight RS, Will RG. Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. Ann Neurol. 2010 Jun;67(6):761-70. doi: 10.1002/ana.21987. PMID:20517937 doi:http://dx.doi.org/10.1002/ana.21987
- ↑ 31.0 31.1 Brandel JP, Preece M, Brown P, Croes E, Laplanche JL, Agid Y, Will R, Alperovitch A. Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet. 2003 Jul 12;362(9378):128-30. doi: 10.1016/S0140-6736(03)13867-6. PMID:12867116 doi:http://dx.doi.org/10.1016/S0140-6736(03)13867-6
- ↑ Kaski D, Mead S, Hyare H, Cooper S, Jampana R, Overell J, Knight R, Collinge J, Rudge P. Variant CJD in an individual heterozygous for PRNP codon 129. Lancet. 2009 Dec 19;374(9707):2128. doi: 10.1016/S0140-6736(09)61568-3. PMID:20109837 doi:http://dx.doi.org/10.1016/S0140-6736(09)61568-3
